EUVIMEDEUVIMED entdecken
Crossref

LncRNA HAR1A inhibits non-small cell lung cancer growth by downregulating c-MYC transcripts and facilitating its proteasomal degradation

Jianqun Ma, Ping Zhang, Yuning Wang, Mengdi Lu, Kui Cao, Shenshui Wei, Cuicui Qi, Xiaodong Ling, Jinhong Zhu

International Immunopharmacology · 2024

DOI: 10.1016/j.intimp.2024.113264 ↗

Kurz gefasst

Fachartikel in der Zeitschrift International Immunopharmacology, 2024. Verfasst von Jianqun Ma und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Thoracic Surgery, Harbin Medical University Cancer Hospital, 150 Haping Road, Harbin 150040, Heilongjiang, China. Hauptthemen laut MEDLINE: Carcinoma, Non-Small-Cell Lung, RNA, Long Noncoding, Lung Neoplasms, Cisplatin. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 71 Literaturangaben. Gefördert von: Harbin Medical University Cancer Hospital, National Natural Science Foundation of China, National Cancer Center.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Non-small cell lung cancer (NSCLC) is a primary cause of cancer-related mortality on a global scale. Research increasingly shows that long non-coding RNAs (lncRNAs) play crucial regulatory roles and serve as biomarkers for diagnosis, prognosis, therapy monitoring, and druggable targets in NSCLC. We previously identified HAR1A as a tumor-suppressing lncRNA in NSCLC, with its loss also observed in oral and hepatocellular carcinoma. This study aimed to expand the understanding of the functional role of HAR1A in NSCLC and uncover its underlying mechanisms. Our results demonstrated that elevating HAR1A levels impeded NSCLC cell proliferation and migration but promoted apoptosis, thereby boosting their susceptibility to cisplatin. Subsequently, we discovered that HAR1A enhanced cisplatin's cytotoxicity in NSCLC cells by curbing adaptive autophagy through the downregulation of MYC. Further analysis revealed that HAR1A suppresses MYC by both lowering its transcript levels and promoting protein ubiquitination and degradation, thereby restricting tumor cell proliferation, migration, and adaptive autophagy. In exploring MYC's targets, we observed that MYC upregulated the transcription of heat shock protein 90 alpha family class B member 1 (HSP90AB1/HSP90β) gene. Rescue experiments verified that HAR1A mitigated NSCLC cell proliferation and migration and induced apoptosis through the MYC/HSP90β axis. Finally, we confirmed that HAR1A overexpression increased cisplatin efficacy in nude mouse NSCLC xenograft models.In conclusion, the findings suggest that HAR1A could be a promising therapeutic target in treating NSCLC and biomarkers for predicting chemotherapy outcomes. This study provides new insights into the molecular mechanisms of chemoresistance in NSCLC and underscores the potential of lncRNA-based strategies in cancer therapy.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Carcinoma, Non-Small-Cell LungRNA, Long NoncodingLung NeoplasmsCisplatinCell ProliferationProto-Oncogene Proteins c-mycGene Expression Regulation, NeoplasticHumansAnimalsCell Line, TumorDown-RegulationCell MovementProteasome Endopeptidase ComplexAntineoplastic AgentsMice, NudeAutophagyMiceApoptosisProteolysisHSP90 Heat-Shock ProteinsA549 CellsMice, Inbred BALB CXenograft Model Antitumor Assays

Stichwörter der Autor:innen

AutophagyChemoresistanceHAR1AHSP90βNSCLCc-MYC

Substanzen

RNA, Long NoncodingCisplatinProto-Oncogene Proteins c-mycProteasome Endopeptidase ComplexAntineoplastic AgentsMYC protein, humanHSP90 Heat-Shock Proteins

Autor:innen und Institutionen

  • Department of Thoracic Surgery, Harbin Medical University Cancer Hospital, 150 Haping Road, Harbin 150040, Heilongjiang, China.
  • Department of Clinical Laboratory, Harbin Medical University Cancer Hospital, 150 Haping Road, Harbin 150040, Heilongjiang, China.
  • Department of Clinical Laboratory, Harbin Medical University Cancer Hospital, 150 Haping Road, Harbin 150040, Heilongjiang, China; Biobank, Harbin Medical University Cancer Hospital, 150 Haping Road, Harbin 150040, Heil…

Förderung

  • Harbin Medical University Cancer Hospital
  • National Natural Science Foundation of China
  • National Cancer Center

Zitieren

APA

Ma, J., Zhang, P., Wang, Y., Lu, M., Cao, K., Wei, S., Qi, C., Ling, X., & Zhu, J. (2024). LncRNA HAR1A inhibits non-small cell lung cancer growth by downregulating c-MYC transcripts and facilitating its proteasomal degradation. International Immunopharmacology. https://doi.org/10.1016/j.intimp.2024.113264

Vancouver

Ma J, Zhang P, Wang Y, Lu M, Cao K, Wei S, et al. LncRNA HAR1A inhibits non-small cell lung cancer growth by downregulating c-MYC transcripts and facilitating its proteasomal degradation. International Immunopharmacology. 2024. doi:10.1016/j.intimp.2024.113264

BibTeX
@article{Ma2024,
  author = {Ma, Jianqun and Zhang, Ping and Wang, Yuning and Lu, Mengdi and Cao, Kui and Wei, Shenshui and Qi, Cuicui and Ling, Xiaodong and Zhu, Jinhong},
  title = {LncRNA HAR1A inhibits non-small cell lung cancer growth by downregulating c-MYC transcripts and facilitating its proteasomal degradation},
  journal = {International Immunopharmacology},
  year = {2024},
  doi = {10.1016/j.intimp.2024.113264}
}
Kostenlos starten →